top of page
Excision Logo home

Focused on Cures

Excision is developing CRISPR-based therapies to cure viral diseases and improve the lives of chronically ill patients

INNOVATIVE

Technology

Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

We are the first company to remove HIV genomes from animals and generate functional cures for HIV.

NOVEL

Approach

SAFE

Targets non-human viral genomes minimizing chance of off-target cuts

CURATIVE

Removes non-human DNA to return the genome to normal or near-normal

EFFICIENT

Excision products require one-time gene edit to remove the viral genome permanently

“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

News

LATEST

GLOBE NEWSWIRE

August 2021

Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

GLOBE NEWSWIRE

April 2024

Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting

GLOBE NEWSWIRE

April 2024

Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024

GLOBE NEWSWIRE

April 2024

OUR

Partners

Johns Hopkins logo
UCB logo
Temple logo
Dartmouth logo
Stanford logo
U Penn logo
UCSF logo
Washington Univ logo
Univ Colorado Denver logo
Cooper UHC logo

134 Coolidge Avenue

Waterton, MA 02472 

© 2024 Excision BioTherapeutics. All Rights Reserved.

bottom of page